MacroGenics (MGNX) Expected to Announce Quarterly Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is projected to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $34.17 million for the quarter.

MacroGenics Price Performance

Shares of NASDAQ:MGNX opened at $2.32 on Wednesday. The firm has a market capitalization of $145.61 million, a PE ratio of -1.47 and a beta of 2.02. The business has a 50 day simple moving average of $2.96 and a two-hundred day simple moving average of $3.34. MacroGenics has a 1 year low of $2.15 and a 1 year high of $21.88.

Analysts Set New Price Targets

A number of research firms recently issued reports on MGNX. StockNews.com upgraded MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. HC Wainwright reiterated a “neutral” rating and set a $4.00 target price on shares of MacroGenics in a research report on Wednesday, November 6th. Finally, JMP Securities cut shares of MacroGenics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, MacroGenics currently has an average rating of “Hold” and an average target price of $7.63.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.